Medication info

Triinwon Tablets 80/10/10mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletAmlodipine Besylate›13.87mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Daewon Pharmaceutical Co., Ltd.
Appearance
White oval film-coated tablets
Packaging
30 tablets (10 tablets x 3)/PTP
Approval status
Active

MFDS item code 201802230 · Approved 2018.05.30

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. Patients taking telmisartan/amlodipine combination therapy together with rosuvastatin as a single agent may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose of each individual ingredient (amlodipine or telmisartan) be adjusted. However, if blood pressure is not controlled with the individual ingredients, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: Dose adjustment is not necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, it is recommended to initiate treatment at a low dose and gradually increase the dose. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients.

Ingredients

Manufacturer
Daewon Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol
  • smoking
  • family history of early coronary artery disease.
View approved original text

This medication is used for patients with essential hypertension whose blood pressure is not sufficiently controlled, in combination with telmisartan and amlodipine, and for patients taking rosuvastatin. The telmisartan/amlodipine combination helps effectively manage blood pressure, improving hypertension. Rosuvastatin calcium is used as an adjunct in patients with hypercholesterolemia (including primary and familial types) who are not adequately controlled by diet. Additionally, this medication slows the progression of atherosclerosis and is beneficial for patients with dysbetalipoproteinemia. In patients with a high risk of cardiovascular disease, it contributes to reducing the need for stroke, myocardial infarction, and arterial revascularization. Therefore, this medication is effectively used in the treatment of hypertension and hyperlipidemia.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. Patients taking telmisartan/amlodipine combination therapy together with rosuvastatin as a single agent may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose of each individual ingredient (amlodipine or telmisartan) be adjusted. However, if blood pressure is not controlled with the individual ingredients, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: Dose adjustment is not necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, it is recommended to initiate treatment at a low dose and gradually increase the dose. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 mg daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients.

Precautions

This medication can cause severe harm to the fetus and newborn during pregnancy; therefore, it should be discontinued immediately if pregnancy is confirmed. Women of childbearing potential must use appropriate contraceptive methods and pregnant or nursing women should not take this medication. Patients with hypersensitivity to any components of this medication or with a history of certain hereditary angioedema, severe liver dysfunction, or severe kidney impairment should not take it. Additionally, patients with severe heart valve disease, shock, or myopathy should not use this medication. Elderly patients or those with hypertension, hyperkalemia, liver dysfunction, etc. should be carefully monitored during administration, paying particular attention to muscle-related adverse symptoms. This medication can cause serious muscle adverse reactions such as myalgia, myopathy, and rarely, rhabdomyolysis; if symptoms like pain, weakness, or cramps occur in the muscles, medical consultation should be sought immediately. Liver function abnormalities may occur, so liver enzyme levels should be monitored regularly and if abnormalities are found, administration should be stopped. This medication may interact with other drugs; therefore, if other medications are being taken, it is essential to inform healthcare providers, especially when combined with certain antibiotics, immunosuppressants, or antihypertensive medications. In case of overdose, symptoms such as hypotension, dizziness, and acute renal failure may occur; therefore, the prescribed dosage must be strictly followed, and in case of overdose, immediate contact with a medical institution is necessary. It is advisable to avoid alcohol or consumption of stimulating foods while taking this medication; caution should be taken when driving or operating machinery as dizziness or drowsiness may occur. This medication is not recommended for children, and it should be stored in a safe place out of reach of children.

Side effects

Viral upper respiratory infection, dyspnea, rectal hemorrhage, dyspepsia, atopic dermatitis, peripheral edema, chronic gastritis, various gastrointestinal disorders, hiatal hernia, dysuria, rhinitis, oropharyngeal discomfort, pulmonary disease, unspecified intestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, headache, dizziness, orthostatic hypotension, low back pain, edema, flushing, palpitations, fatigue, nausea, abdominal pain, drowsiness, arrhythmia, bradycardia, chest pain, peripheral ischemia, syncope, postural hypotension, vasculitis, peripheral neuropathy, sensory abnormalities, tremors, loss of appetite, constipation, dysphagia, diarrhea, flatulence, pancreatitis, vomiting, gingival hyperplasia, allergic reactions, burning sensation, malaise, pain, rigidity, weight gain, weight loss, erectile dysfunction, insomnia, neuralgia, depression, abnormal dreams, anxiety, depersonalization, angioedema, erythema multiforme, pruritus, rash, erythematous rash, papular rash, visual disturbances, conjunctivitis, diplopia, ocular pain, ear pain, frequent urination, urinary disorders, nocturia, dry mouth, increased sweating, hyperglycemia, thirst, leukopenia, purpura, thrombocytopenia, angioedema, headache, weakness, cough, asthenia, facial edema, limb swelling, hypersensitivity reactions, increased sweating, erythema, atrial fibrillation, congestive heart failure, myocardial infarction, elevated blood pressure, worsening hypertension, hypotension, hyperkalemia, hypoglycemia, syncope, urinary tract infection, erectile dysfunction, muscle cramps, myalgia, bradycardia, eosinophilia, thrombocytopenia, increased uric acid, liver dysfunction, liver disease, acute renal failure, anemia, elevated CPK, anaphylactic reaction, tendon pain, erectile dysfunction, constipation, nausea, abdominal pain, pruritus, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, joint pain, fatigue, numbness, sensory abnormalities, chest discomfort, loss of appetite, abdominal distension, myopathy, myositis, rhabdomyolysis, palpitations, insomnia, migraine, vertigo, sensory abnormalities, involuntary muscle contractions, insomnia, drowsiness, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, lupus-like syndrome, muscle rupture, memory loss, peripheral neuropathy, cough, dyspnea, hematuria, edema, gynecomastia, interstitial lung disease, severe muscle weakness, oculobulbar weakness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that does not allow light in. Additionally, it is recommended to store it at room temperature between 1 degree and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness.

Appearance and packaging

Appearance

White oval film-coated tablets

Package unit

30 tablets (10 tablets x 3)/PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.